Shares of Biogen are little changed following the resumption of trade in pre-market session at $285.30. Shares were halted after the close last night ahead of the FDA announcement to approve the supplemental Biologics License Application supporting the traditional approval of LEQEMBI 100 mg/mL injection for intravenous use, making the drug the first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline in adults with Alzheimer’s disease.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BIIB:
- Label for Biogen’s Leqembi generally as expected, says Mizuho
- Black box warning on Leqembi ‘bit if a surprise,’ says Piper Sandler
- Biogen set up nicely to generate upside, says Canaccord
- Piper Sandler pharmaceuticals analysts to hold analyst/industry conference call
- Biogen, Eisai’s Alzheimer’s Drug Scores Big With FDA’s Full Approval